{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:05:02Z","timestamp":1783926302920,"version":"3.55.0"},"reference-count":307,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032486","name":"Qatar Research, Development and Innovation Council","doi-asserted-by":"publisher","award":["ARG02-0421-240249"],"award-info":[{"award-number":["ARG02-0421-240249"]}],"id":[{"id":"10.13039\/100032486","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejmech.2026.118987","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T23:12:57Z","timestamp":1779750777000},"page":"118987","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Antiparasitic agents in oncology: Innovative mechanisms, emerging evidence and clinical potential in cancer treatment"],"prefix":"10.1016","volume":"316","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-429X","authenticated-orcid":false,"given":"Raed M.","family":"Al-Zoubi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2848-8698","authenticated-orcid":false,"given":"Alaa","family":"Farhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8489-5873","authenticated-orcid":false,"given":"Basma","family":"Hanbali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6747-9927","authenticated-orcid":false,"given":"Sally R.","family":"Al-Zoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4168-8548","authenticated-orcid":false,"given":"Abbas","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6748-3663","authenticated-orcid":false,"given":"Mohanad","family":"Shkoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7435-9751","authenticated-orcid":false,"given":"Abdulilah D.","family":"Bani-Yaseen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0248-4777","authenticated-orcid":false,"given":"Mazhar Salim","family":"Al Zoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelali","family":"Agouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejmech.2026.118987_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2991\/jegh.k.191008.001","article-title":"Current cancer epidemiology","volume":"9","author":"Mattiuzzi","year":"2019","journal-title":"J Epidemiol Glob Health"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib2","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118987_bib3","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1001\/jamainternmed.2017.3601","article-title":"Research and development spending to bring a single cancer drug to market and revenues after approval","volume":"177","author":"Prasad","year":"2017","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.ejmech.2026.118987_bib4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.semcancer.2020.03.011","article-title":"Drug rechanneling: a novel paradigm for cancer treatment","volume":"68","author":"Kaushik","year":"2021","journal-title":"Semin. Cancer Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118987_bib5","first-page":"192","article-title":"Drug repositioning, an approach for identification of new","volume":"1","author":"Yaseen","year":"2019","journal-title":"J Nat Appl Sci Pakistan"},{"key":"10.1016\/j.ejmech.2026.118987_bib6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.semcancer.2019.09.012","article-title":"Drug repurposing for breast cancer therapy: old weapon for new battle","volume":"68","author":"Aggarwal","year":"2021","journal-title":"Semin. Cancer Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118987_bib7","first-page":"651","article-title":"New drugs are not enough-drug repositioning in oncology: an update","volume":"56","author":"Armando","year":"2020","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib8","first-page":"5","article-title":"Anthelmintic flubendazole and its potential use in anticancer therapy","volume":"60","author":"\u010c\u00e1\u0148ov\u00e1","year":"2017","journal-title":"Acta Med."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118987_bib9","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118987_bib10","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.7150\/ijbs.24612","article-title":"Review of drug repositioning approaches and resources","volume":"14","author":"Xue","year":"2018","journal-title":"Int. J. Biol. Sci."},{"issue":"14","key":"10.1016\/j.ejmech.2026.118987_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21144957","article-title":"Repositioning of anthelmintic drugs for the treatment of cancers of the digestive system","volume":"21","author":"Laudisi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118987_bib12","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.2147\/IDR.S332378","article-title":"Anthelmintic resistance and its mechanism: a review","volume":"14","author":"Fissiha","year":"2021","journal-title":"Infect. Drug Resist."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118987_bib13","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/ptr.6332","article-title":"Dihydroartemisinin, an antimalarial drug, induces absent in melanoma 2 inflammasome activation and autophagy in human hepatocellular carcinoma HepG2215 cells","volume":"33","author":"Shi","year":"2019","journal-title":"Phytother Res."},{"issue":"32","key":"10.1016\/j.ejmech.2026.118987_bib14","doi-asserted-by":"crossref","first-page":"33769","DOI":"10.18632\/oncotarget.5615","article-title":"Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration","volume":"6","author":"Xiang","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7607","key":"10.1016\/j.ejmech.2026.118987_bib16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/534314a","article-title":"Can you teach old drugs new tricks?","volume":"534","author":"Nosengo","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118987_bib17","series-title":"WHO Model List of Essential Medicinesl 23rd List. Geneva","year":"2023"},{"key":"10.1016\/j.ejmech.2026.118987_bib18","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3332\/ecancer.2014.485","article-title":"Repurposing drugs in oncology (ReDO)-mebendazole as an anti-cancer agent","volume":"8","author":"Pantziarka","year":"2014","journal-title":"ecancermedicalscience"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118987_bib19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc1317","article-title":"Microtubules as a target for anticancer drugs","volume":"4","author":"Jordan","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.ejmech.2026.118987_bib20","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nrd3253","article-title":"Microtubule-binding agents: a dynamic field of cancer therapeutics","volume":"9","author":"Dumontet","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118987_bib21","doi-asserted-by":"crossref","DOI":"10.4110\/in.2020.20.e29","article-title":"The antitumor potentials of benzimidazole anthelmintics as repurposing drugs","volume":"20","author":"Son","year":"2020","journal-title":"Immune Netw."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118987_bib22","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10495-011-0673-2","article-title":"ER stress sensitizes cells to TRAIL through down-regulation of FLIP and Mcl-1 and PERK-dependent up-regulation of TRAIL-R2","volume":"17","author":"Mart\u00edn-P\u00e9rez","year":"2012","journal-title":"Apoptosis"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118987_bib23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrclinonc.2010.21","article-title":"mTOR signaling and drug development in cancer","volume":"7","author":"Dancey","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118987_bib24","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.bbrc.2015.12.059","article-title":"Pyrvinium selectively induces apoptosis of lymphoma cells through impairing mitochondrial functions and JAK2\/STAT5","volume":"469","author":"Xiao","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118987_bib25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2174\/138945006776359412","article-title":"Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells","volume":"7","author":"Efferth","year":"2006","journal-title":"Curr. Drug Targets"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118987_bib26","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.21873\/anticanres.14082","article-title":"Antihelminthic niclosamide induces autophagy and delayed apoptosis in human non-small lung cancer cells <em>In Vitro<\/em> and <em>In vivo<\/em>","volume":"40","author":"Chai","year":"2020","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejmech.2026.118987_bib27","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bcp.2018.11.003","article-title":"Non-mitotic effect of albendazole triggers apoptosis of human leukemia cells via SIRT3\/ROS\/p38 MAPK\/TTP axis-mediated TNF-\u03b1 upregulation","volume":"162","author":"Wang","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118987_bib28","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","article-title":"Wnt\/\u03b2-catenin signaling and disease","volume":"149","author":"Clevers","year":"2012","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.ejmech.2026.118987_bib29","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.15252\/emmm.201404084","article-title":"The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer","volume":"6","author":"Melotti","year":"2014","journal-title":"EMBO Mol. Med."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118987_bib30","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nchembio.453","article-title":"Small-molecule inhibition of Wnt signaling through activation of casein kinase 1\u03b1","volume":"6","author":"Thorne","year":"2010","journal-title":"Nat. Chem. Biol."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118987_bib31","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118987_bib32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cellsig.2017.04.001","article-title":"Beyond an antihelminthic drug","volume":"41","author":"Chen","year":"2018","journal-title":"Cell. Signal."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ccr.2012.11.017","article-title":"Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists","volume":"23","author":"Kim","year":"2013","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.ejmech.2026.118987_bib34","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/nm.4409","article-title":"Cancer stem cells revisited","volume":"23","author":"Batlle","year":"2017","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118987_bib35","first-page":"317","article-title":"The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug","volume":"8","author":"Juarez","year":"2018","journal-title":"Am. J. Cancer Res."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118987_bib36","first-page":"3397","article-title":"Ivermectin as an inhibitor of cancer stem-like cells","volume":"17","author":"Dominguez-Gomez","year":"2018","journal-title":"Mol. Med. Rep."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118987_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029290","article-title":"Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt\/\u03b2-catenin pathway","volume":"6","author":"Lu","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118987_bib38","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3892\/ijo.2016.3337","article-title":"WNT pathway inhibitor pyrvinium pamoate inhibits the self-renewal and metastasis of breast cancer stem cells","volume":"48","author":"Xu","year":"2016","journal-title":"Int. J. Oncol."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118987_bib39","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118987_bib40","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1128\/AAC.01696-12","article-title":"Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains","volume":"57","author":"Lim","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib41","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118987_bib42","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1472-8206.2009.00684.x","article-title":"Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway","volume":"23","author":"Ci","year":"2009","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"22","key":"10.1016\/j.ejmech.2026.118987_bib43","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.7150\/jca.26948","article-title":"Niclosamide inhibits cell growth and enhances drug sensitivity of hepatocellular carcinoma cells via STAT3 signaling pathway","volume":"9","author":"Wang","year":"2018","journal-title":"J. Cancer"},{"key":"10.1016\/j.ejmech.2026.118987_bib44","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/2481907","article-title":"Artesunate restrains maturation of dendritic cells and ameliorates heart transplantation-induced acute rejection in mice through the PERK\/ATF4\/CHOP signaling pathway","volume":"2021","author":"Chen","year":"2021","journal-title":"Mediat. Inflamm."},{"issue":"42","key":"10.1016\/j.ejmech.2026.118987_bib45","doi-asserted-by":"crossref","first-page":"68571","DOI":"10.18632\/oncotarget.11851","article-title":"Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model","volume":"7","author":"Williamson","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.ejmech.2026.118987_bib46","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ja.2017.11","article-title":"Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations","volume":"70","author":"Crump","year":"2017","journal-title":"J. Antibiot. (Tokyo)"},{"issue":"8","key":"10.1016\/j.ejmech.2026.118987_bib47","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1073\/pnas.0915125107","article-title":"Repositioning of an existing drug for the neglected tropical disease onchocerciasis","volume":"107","author":"Gloeckner","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"4613","key":"10.1016\/j.ejmech.2026.118987_bib48","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.6308762","article-title":"Ivermectin: a potent new antiparasitic agent","volume":"221","author":"Campbell","year":"1983","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.ejmech.2026.118987_bib49","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1039\/C5NP90043C","article-title":"Recognition of the role of natural products as drugs to treat neglected tropical diseases by the 2015 nobel prize in physiology or medicine","volume":"32","author":"McKerrow","year":"2015","journal-title":"Nat. Prod. Rep."},{"issue":"10180","key":"10.1016\/j.ejmech.2026.118987_bib50","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S0140-6736(18)32321-3","article-title":"Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial","volume":"393","author":"Foy","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118987_bib51","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4103\/0972-9062.213454","article-title":"Effect of ivermectin on Trypanosoma brucei brucei in experimentally infected mice","volume":"49","author":"Udensi","year":"2012","journal-title":"J. Vector Borne Dis."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118987_bib52","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/ja.2017.31","article-title":"Ivermectin efficacy against Biomphalaria, intermediate host snail vectors of schistosomiasis","volume":"70","author":"Katz","year":"2017","journal-title":"J. Antibiot. (Tokyo)"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118987_bib53","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3347\/kjp.2013.51.3.297","article-title":"Therapeutic potential of myrrh and ivermectin against experimental Trichinella spiralis infection in mice","volume":"51","author":"Basyoni","year":"2013","journal-title":"Kor. J. Parasitol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib54","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/vbz.2009.0030","article-title":"Effects of ivermectin on blood-feeding Phlebotomus papatasi, and the promastigote stage of Leishmania major","volume":"11","author":"Hanafi","year":"2011","journal-title":"Vector Borne Zoonotic Dis."},{"key":"10.1016\/j.ejmech.2026.118987_bib55","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2147\/DDDT.S237393","article-title":"Progress in understanding the molecular mechanisms underlying the antitumour effects of ivermectin","volume":"14","author":"Liu","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118987_bib56","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/BF00637608","article-title":"The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution","volume":"35","author":"Edwards","year":"1988","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib57","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1208\/s12248-007-9000-9","article-title":"The pharmacokinetics and interactions of ivermectin in humans\u2014A mini-review","volume":"10","author":"Gonz\u00e1lez","year":"2008","journal-title":"AAPS J."},{"issue":"Database issue","key":"10.1016\/j.ejmech.2026.118987_bib58","doi-asserted-by":"crossref","first-page":"D237","DOI":"10.1093\/nar\/gkp970","article-title":"SuperCYP: a comprehensive database on cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions","volume":"38","author":"Preissner","year":"2010","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118987_bib59","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1172\/JCI118214","article-title":"Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A","volume":"96","author":"Schinkel","year":"1995","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib60","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/jps.22262","article-title":"Ivermectin interacts with human ABCG2","volume":"100","author":"Jani","year":"2011","journal-title":"J. Pharmacol. Sci."},{"issue":"25","key":"10.1016\/j.ejmech.2026.118987_bib61","doi-asserted-by":"crossref","first-page":"13949","DOI":"10.1073\/pnas.240464697","article-title":"Drug-resistant Drosophila indicate glutamate-gated chloride channels are targets for the antiparasitics nodulisporic acid and ivermectin","volume":"97","author":"Kane","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118987_bib62","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1073\/pnas.76.4.2062","article-title":"Avermectin B1a irreversibly blocks postsynaptic potentials at the lobster neuromuscular junction by reducing muscle membrane resistance","volume":"76","author":"Fritz","year":"1979","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib63","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s40001-023-01275-4","article-title":"Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects","volume":"28","author":"Mohi-Ud-Din","year":"2023","journal-title":"Eur. J. Med. Res."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118987_bib64","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.amjms.2019.11.001","article-title":"Ivermectin augments the in vitro and in vivo efficacy of Cisplatin in epithelial ovarian cancer by suppressing Akt\/mTOR signaling","volume":"359","author":"Zhang","year":"2020","journal-title":"Am. J. Med. Sci."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118987_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/antiox11050908","article-title":"Ivermectin-induced apoptotic cell death in human SH-SY5Y cells involves the activation of oxidative stress and mitochondrial pathway and Akt\/mTOR-Pathway-Mediated autophagy","volume":"11","author":"Zhang","year":"2022","journal-title":"Antioxidants"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib66","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12917-019-2026-2","article-title":"Ivermectin inhibits canine mammary tumor growth by regulating cell cycle progression and WNT signaling","volume":"15","author":"Diao","year":"2019","journal-title":"BMC Vet. Res."},{"key":"10.1016\/j.ejmech.2026.118987_bib67","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.pestbp.2019.10.011","article-title":"Ivermectin-induced programmed cell death and disruption of mitochondrial membrane potential in bovine mammary gland epithelial cells","volume":"163","author":"Park","year":"2020","journal-title":"Pestic. Biochem. Physiol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib68","doi-asserted-by":"crossref","first-page":"28","DOI":"10.58803\/RBES.2022.1.1.06","article-title":"A summary of autophagy mechanisms in cancer cells","volume":"1","author":"Sahebi","year":"2022","journal-title":"Research in Biotechnology and Environmental Science"},{"issue":"12","key":"10.1016\/j.ejmech.2026.118987_bib69","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1158\/1078-0432.CCR-09-2824","article-title":"Cancer stem cells and self-renewal","volume":"16","author":"O'Brien","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"37","key":"10.1016\/j.ejmech.2026.118987_bib70","doi-asserted-by":"crossref","first-page":"39550","DOI":"10.18632\/oncotarget.6098","article-title":"Differentiation and transdifferentiation potentials of cancer stem cells","volume":"6","author":"Huang","year":"2015","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.ejmech.2026.118987_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101527","article-title":"The PAK1-Stat3 signaling pathway activates IL-6 gene transcription and human breast cancer stem cell formation","volume":"11","author":"Kim","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118987_bib72","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cbi.2005.11.002","article-title":"Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3)","volume":"159","author":"Lespine","year":"2006","journal-title":"Chem. Biol. Interact."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib73","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0006-2952(96)00656-9","article-title":"Reversal of P-glycoprotein-associated multidrug resistance by ivermectin","volume":"53","author":"Pouliot","year":"1997","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib74","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13046-019-1251-7","article-title":"Ivermectin reverses the drug resistance in cancer cells through EGFR\/ERK\/Akt\/NF-\u03baB pathway","volume":"38","author":"Jiang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118987_bib75","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/00001813-199609000-00005","article-title":"The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor","volume":"7","author":"Didier","year":"1996","journal-title":"Anti Cancer Drugs"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118987_bib76","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1172\/JCI130819","article-title":"Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models","volume":"130","author":"Nappi","year":"2020","journal-title":"J. Clin. Investig."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118987_bib77","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.21873\/anticanres.13669","article-title":"Anti-parasitic drug ivermectin exhibits potent anticancer activity against gemcitabine-resistant cholangiocarcinoma in vitro","volume":"39","author":"Intuyod","year":"2019","journal-title":"Anticancer Res."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118987_bib78","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrc1892","article-title":"p21-activated kinases in cancer","volume":"6","author":"Kumar","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.ejmech.2026.118987_bib79","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1136\/gutjnl-2014-306768","article-title":"Tracing PAKs from GI inflammation to cancer","volume":"63","author":"Dammann","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.ejmech.2026.118987_bib80","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/bs.acr.2016.01.002","article-title":"PAKs in human cancer progression: from inception to cancer therapeutic to future oncobiology","volume":"130","author":"Kumar","year":"2016","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118987_bib81","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.2147\/DDDT.S172538","article-title":"Macrocyclic lactones inhibit nasopharyngeal carcinoma cells proliferation through PAK1 inhibition and reduce in vivo tumor growth","volume":"12","author":"Gallardo","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2026.118987_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.clsc.2016.05.001","article-title":"Macrocyclic lactones block melanoma growth, metastases development and potentiate activity of Anti\u2013BRAF V600 inhibitors","volume":"1","author":"Gallardo","year":"2016","journal-title":"Clinical Skin Cancer"},{"issue":"15","key":"10.1016\/j.ejmech.2026.118987_bib83","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1158\/0008-5472.CAN-15-2887","article-title":"Ivermectin induces cytostatic autophagy by blocking the PAK1\/Akt axis in breast cancer","volume":"76","author":"Dou","year":"2016","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib84","doi-asserted-by":"crossref","DOI":"10.3390\/diseases11010049","article-title":"Ivermectin augments the anti-cancer activity of pitavastatin in ovarian cancer cells","volume":"11","author":"Jawad","year":"2023","journal-title":"Diseases"},{"issue":"18","key":"10.1016\/j.ejmech.2026.118987_bib85","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14184357","article-title":"Pitavastatin and ivermectin enhance the efficacy of paclitaxel in chemoresistant high-grade serous carcinoma","volume":"14","author":"Nunes","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2026.118987_bib86","article-title":"Ivermectin has new application in inhibiting colorectal cancer cell growth","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118987_bib89","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00280-020-04041-z","article-title":"Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug","volume":"85","author":"Juarez","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib90","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41523-021-00229-5","article-title":"Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer","volume":"7","author":"Draganov","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"10","key":"10.1016\/j.ejmech.2026.118987_bib91","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.7150\/ijms.76623","article-title":"Ivermectin induces cell cycle arrest and caspase-dependent apoptosis in human urothelial carcinoma cells","volume":"19","author":"Tung","year":"2022","journal-title":"Int. J. Med. Sci."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118987_bib92","first-page":"4502","article-title":"Ivermectin inhibits tumor metastasis by regulating the Wnt\/\u03b2-catenin\/integrin \u03b21\/FAK signaling pathway","volume":"12","author":"Jiang","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118987_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.625991","article-title":"Computational drug repositioning and experimental validation of ivermectin in treatment of gastric cancer","volume":"12","author":"Rabben","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118987_bib94","article-title":"Drug repurposing of Ivermectin abrogates neutrophil extracellular traps and prevents melanoma metastasis","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib87","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3390\/nursrep13010030","article-title":"Outcome of ivermectin in cancer treatment: an experience in Loja-Ecuador","volume":"13","author":"Jim\u00e9nez-Gaona","year":"2023","journal-title":"Nurs Rep"},{"issue":"16_suppl","key":"10.1016\/j.ejmech.2026.118987_bib88","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e13146","article-title":"A phase I\/II study evaluating the safety and efficacy of ivermectin in combination with balstilimab in patients with metastatic triple negative breast cancer","volume":"43","author":"Yuan","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.ejmech.2026.118987_bib95","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1002\/slct.202100671","article-title":"Palladium-catalyzed regioselective coupling of amidines and 1,2,3-Triiodobenzenes: facile synthesis of 2,3-Diiodinated N-Arylbenzimidamides as potential MDM2 and MDM4 inhibitors","volume":"6","author":"Al-Zoubi","year":"2021","journal-title":"ChemistrySelect"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118987_bib96","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.apsb.2022.09.010","article-title":"Benzimidazole and its derivatives as cancer therapeutics: the potential role from traditional to precision medicine","volume":"13","author":"Lee","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118987_bib97","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jama.1971.03190030039008","article-title":"Mebendazole in enterobiasis. Radiochemical and pilot clinical study in 1,278 subjects","volume":"217","author":"Brugmans","year":"1971","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib98","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2125.1985.tb02616.x","article-title":"The pharmacokinetics and bioavailability of a tracer dose of [3H]- mebendazole in man","volume":"19","author":"Dawson","year":"1985","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118987_bib99","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2125.1982.tb02008.x","article-title":"The pharmacokinetics and bioavailability of mebendazole in man: a pilot study using [3H]-mebendazole","volume":"14","author":"Dawson","year":"1982","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118987_bib100","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00542462","article-title":"Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease","volume":"22","author":"Braithwaite","year":"1982","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118987_bib101","first-page":"633","article-title":"Serum concentrations of mebendazole in patients with hydatid disease","volume":"23","author":"Bekhti","year":"1985","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"issue":"15","key":"10.1016\/j.ejmech.2026.118987_bib102","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-14-2681","article-title":"Brain penetration and efficacy of different mebendazole polymorphs in a mouse brain tumor model","volume":"21","author":"Bai","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118987_bib103","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11091284","article-title":"Mebendazole as a candidate for drug repurposing in oncology: an extensive review of current literature","volume":"11","author":"Guerini","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib104","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13058-022-01591-3","article-title":"Mebendazole prevents distant organ metastases in part by decreasing ITG\u03b24 expression and cancer stemness","volume":"24","author":"Joe","year":"2022","journal-title":"Breast Cancer Res."},{"issue":"23","key":"10.1016\/j.ejmech.2026.118987_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27238127","article-title":"Mebendazole impedes the proliferation and migration of pancreatic cancer cells through SK1 inhibition dependent pathway","volume":"27","author":"Limbu","year":"2022","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.ejmech.2026.118987_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e16996","article-title":"Budding uninhibited by benzimidazoles 1 promotes cell proliferation, invasion, and epithelial-mesenchymal transition via the Wnt\/\u03b2-catenin signaling in glioblastoma","volume":"9","author":"Zhang","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.ejmech.2026.118987_bib107","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cbi.2018.07.026","article-title":"Flubendazole and mebendazole impair migration and epithelial to mesenchymal transition in oral cell lines","volume":"293","author":"Kralova","year":"2018","journal-title":"Chem. Biol. Interact."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118987_bib108","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1158\/1541-7786.MCR-07-2159","article-title":"Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells","volume":"6","author":"Doudican","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118987_bib109","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2119\/molmed.2017.00011","article-title":"Repurposing mebendazole as a replacement for vincristine for the treatment of brain tumors","volume":"23","author":"De Witt","year":"2017","journal-title":"Mol. Med."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118987_bib110","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/neuonc\/nou234","article-title":"Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis","volume":"17","author":"Bai","year":"2015","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib111","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55666-x","article-title":"Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma","volume":"9","author":"Younis","year":"2019","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118987_bib112","doi-asserted-by":"crossref","first-page":"12576","DOI":"10.18632\/oncotarget.14990","article-title":"The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma","volume":"8","author":"Simbulan-Rosenthal","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.ejmech.2026.118987_bib131","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.tiv.2015.08.007","article-title":"The anthelmintic drug mebendazole inhibits growth, migration and invasion in gastric cancer cell model","volume":"29","author":"Pinto","year":"2015","journal-title":"Toxicol. Vitro"},{"issue":"8","key":"10.1016\/j.ejmech.2026.118987_bib132","doi-asserted-by":"crossref","first-page":"12968","DOI":"10.18632\/oncotarget.14673","article-title":"Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC)","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib133","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijrobp.2018.08.046","article-title":"Mebendazole potentiates radiation therapy in triple-negative breast cancer","volume":"103","author":"Zhang","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118987_bib113","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.4158\/EP10390.CR","article-title":"Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma","volume":"17","author":"Dobrosotskaya","year":"2011","journal-title":"Endocr. Pract."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118987_bib114","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/0284186X.2013.844359","article-title":"Drug repositioning from bench to bedside: tumour remission by the antihelmintic drug mebendazole in refractory metastatic colon cancer","volume":"53","author":"Nygren","year":"2014","journal-title":"Acta Oncol."},{"key":"10.1016\/j.ejmech.2026.118987_bib115","unstructured":"."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib116","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1128\/CMR.14.1.150-164.2001","article-title":"Drug targets and mechanisms of resistance in the anaerobic protozoa","volume":"14","author":"Upcroft","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2026.118987_bib117","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.redox.2016.09.013","article-title":"Albendazole as a promising molecule for tumor control","volume":"10","author":"Castro","year":"2016","journal-title":"Redox Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib118","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0304-3835(01)00382-2","article-title":"In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole","volume":"165","author":"Pourgholami","year":"2001","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118987_bib119","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.bcp.2007.05.006","article-title":"Epothilone-paclitaxel resistant leukemic cells CEM\/dEpoB300 are sensitive to albendazole: involvement of apoptotic pathways","volume":"74","author":"Khalilzadeh","year":"2007","journal-title":"Biochem. Pharmacol."},{"issue":"10","key":"10.1016\/j.ejmech.2026.118987_bib120","first-page":"3791","article-title":"Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole","volume":"29","author":"Chu","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejmech.2026.118987_bib121","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-025-03223-3","article-title":"Amorphization of albendazole using organic acid-based solid dispersions for improved dissolution: a solvent-free approach","volume":"26","author":"Jambukiya","year":"2025","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118987_bib122","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0001-706X(03)00031-7","article-title":"Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics","volume":"86","author":"Dayan","year":"2003","journal-title":"Acta Trop."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118987_bib123","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02489-18","article-title":"Pharmacokinetics of albendazole, albendazole sulfoxide, and albendazole sulfone determined from plasma, blood, dried-blood spots, and mitra samples of hookworm-infected adolescents","volume":"63","author":"Schulz","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"20","key":"10.1016\/j.ejmech.2026.118987_bib124","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.2217\/nnm-2017-0102","article-title":"Nanoformulations of albendazole as effective anticancer and antiparasite agents","volume":"12","author":"Movahedi","year":"2017","journal-title":"Nanomedicine (Lond)."},{"key":"10.1016\/j.ejmech.2026.118987_bib125","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.redox.2016.09.013","article-title":"Albendazole as a promising molecule for tumor control","volume":"10","author":"Castro","year":"2016","journal-title":"Redox Biol."},{"key":"10.1016\/j.ejmech.2026.118987_bib126","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1471-2407-10-143","article-title":"Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole","volume":"10","author":"Pourgholami","year":"2010","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118987_bib127","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.bbrc.2010.06.019","article-title":"Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis","volume":"397","author":"Pourgholami","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118987_bib128","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103349","article-title":"Altered antioxidant system stimulates dielectric barrier discharge plasma-induced cell death for solid tumor cell treatment","volume":"9","author":"Kaushik","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118987_bib129","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1179\/135100004225004751","article-title":"A comparative study of albendazole and mebendazole-induced, time-dependent oxidative stress","volume":"9","author":"Locatelli","year":"2004","journal-title":"Redox Rep."},{"key":"10.1016\/j.ejmech.2026.118987_bib130","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.redox.2015.08.021","article-title":"Ellagic acid, a polyphenolic compound, selectively induces ROS-mediated apoptosis in cancerous B-lymphocytes of CLL patients by directly targeting mitochondria","volume":"6","author":"Salimi","year":"2015","journal-title":"Redox Biol."},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2026.118987_bib137","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11010-016-2927-3","article-title":"Albendazole inhibits HIF-1\u03b1-dependent glycolysis and VEGF expression in non-small cell lung cancer cells","volume":"428","author":"Zhou","year":"2017","journal-title":"Mol. Cell. Biochem."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118987_bib138","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s12282-019-01027-5","article-title":"(18)F-FDG PET imaging for monitoring the early anti-tumor effect of albendazole on triple-negative breast cancer","volume":"27","author":"Liu","year":"2020","journal-title":"Breast Cancer"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib139","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000055351","article-title":"Pilot study of albendazole in patients with advanced malignancy. Effect on serum tumor markers\/high incidence of neutropenia","volume":"61","author":"Morris","year":"2001","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118987_bib140","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00280-009-1157-8","article-title":"Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer","volume":"65","author":"Pourgholami","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118987_bib141","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0304-4165(80)90431-6","article-title":"Interaction of anthelmintic benzimidazoles with Ascaris suum embryonic tubulin","volume":"630","author":"Friedman","year":"1980","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118987_bib142","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/0169-4758(90)90227-U","article-title":"Mode of action of benzimidazoles","volume":"6","author":"Lacey","year":"1990","journal-title":"Parasitol. Today"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118987_bib143","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/cbdd.14236","article-title":"Recent advances of benzimidazole as anticancer agents","volume":"102","author":"Venugopal","year":"2023","journal-title":"Chem. Biol. Drug Des."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118987_bib144","first-page":"180","article-title":"The pharmacokinetics of mebendazole and flubendazole in animals and man","volume":"256","author":"Michiels","year":"1982","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.ejmech.2026.118987_bib145","first-page":"719","volume":"vol. 77","author":"Vanden Bossche","year":"1985"},{"key":"10.1016\/j.ejmech.2026.118987_bib146","article-title":"Drug repurposing and relabeling for cancer therapy: emerging benzimidazole antihelminthics with potent anticancer effects","volume":"258","author":"Nath","year":"2020","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118987_bib147","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/mutage\/gev070","article-title":"Genotoxicity of flubendazole and its metabolites in vitro and the impact of a new formulation on in vivo aneugenicity","volume":"31","author":"Tweats","year":"2016","journal-title":"Mutagenesis"},{"issue":"9","key":"10.1016\/j.ejmech.2026.118987_bib148","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.drudis.2011.11.007","article-title":"Bridging solubility between drug discovery and development","volume":"17","author":"Di","year":"2012","journal-title":"Drug Discov. Today"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118987_bib149","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1021\/acs.jced.8b01126","article-title":"Solubility modeling and solvent effect for flubendazole in 12 neat solvents","volume":"64","author":"Ma","year":"2019","journal-title":"J. Chem. Eng. Data"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118987_bib150","first-page":"180","article-title":"The pharmacokinetics of mebendazole and flubendazole in animals and man","volume":"256","author":"Michiels","year":"1982","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"issue":"3\u20134","key":"10.1016\/j.ejmech.2026.118987_bib151","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.vetpar.2012.02.008","article-title":"Import and efflux of flubendazole in Haemonchus contortus strains susceptible and resistant to anthelmintics","volume":"187","author":"B\u00e1rt\u00edkov\u00e1","year":"2012","journal-title":"Vet. Parasitol."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118987_bib152","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1016\/j.xphs.2016.03.003","article-title":"Evaluation of three amorphous drug delivery technologies to improve the oral absorption of flubendazole","volume":"105","author":"Vialpando","year":"2016","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2026.118987_bib153","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.actatropica.2018.08.010","article-title":"Efficiency of flubendazole-loaded mPEG-PCL nanoparticles: a promising formulation against the protoscoleces and cysts of Echinococcus granulosus","volume":"187","author":"Farhadi","year":"2018","journal-title":"Acta Trop."},{"issue":"23","key":"10.1016\/j.ejmech.2026.118987_bib154","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2009-09-243055","article-title":"The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma","volume":"115","author":"Spagnuolo","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib155","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23010519","article-title":"Flubendazole plays an important anti-tumor role in different types of cancers","volume":"23","author":"Chen","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118987_bib156","doi-asserted-by":"crossref","first-page":"6326","DOI":"10.18632\/oncotarget.3436","article-title":"Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells","volume":"6","author":"Hou","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.ejmech.2026.118987_bib157","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1002\/ijc.31585","article-title":"Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition","volume":"143","author":"Oh","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"18","key":"10.1016\/j.ejmech.2026.118987_bib158","doi-asserted-by":"crossref","first-page":"8080","DOI":"10.7150\/thno.43473","article-title":"Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in triple-negative breast cancer","volume":"10","author":"Zhen","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2026.118987_bib159","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.680600","article-title":"Flubendazole elicits antitumor effects by inhibiting STAT3 and activating autophagy in non-small cell lung cancer","volume":"9","author":"Xie","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118987_bib160","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41419-022-04823-8","article-title":"Flubendazole induces mitochondrial dysfunction and DRP1-mediated mitophagy by targeting EVA1A in breast cancer","volume":"13","author":"Zhen","year":"2022","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib161","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s13046-019-1303-z","article-title":"Flubendazole demonstrates valid antitumor effects by inhibiting STAT3 and activating autophagy","volume":"38","author":"Lin","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118987_bib162","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2147\/OTT.S193206","article-title":"The anthelmintic drug flubendazole induces cell apoptosis and inhibits NF-\u03baB signaling in esophageal squamous cell carcinoma","volume":"12","author":"Tao","year":"2019","journal-title":"OncoTargets Ther."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib164","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41392-023-01559-5","article-title":"Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies","volume":"8","author":"Jing","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.118987_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105305","article-title":"Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer","volume":"164","author":"Zhou","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.118987_bib166","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3389\/fphar.2019.00600","article-title":"Carbonyl reduction of flubendazole in the human liver: strict stereospecificity, sex difference, low risk of drug interactions","volume":"10","author":"Kub\u00ed\u010dek","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118987_bib167","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.canlet.2017.10.020","article-title":"Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer","volume":"412","author":"Kim","year":"2018","journal-title":"Cancer Lett."},{"issue":"20","key":"10.1016\/j.ejmech.2026.118987_bib163","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242015121","article-title":"Flubendazole enhances the inhibitory effect of paclitaxel via HIF1\u03b1\/PI3K\/AKT signaling pathways in breast cancer","volume":"24","author":"Zhou","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"Pt 1","key":"10.1016\/j.ejmech.2026.118987_bib168","article-title":"Flubendazole inhibits cervical carcinoma by targeting DHODH to induce ferroptosis and mitophagy","volume":"242","author":"Liu","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118987_bib169","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/bs.apar.2018.08.002","article-title":"Drug combinations against soil-transmitted helminth infections","volume":"103","author":"Moser","year":"2019","journal-title":"Adv. Parasitol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib170","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0166-6851(99)00169-3","article-title":"Multiple lethal effects induced by a benzimidazole anthelmintic in the anterior intestine of the nematode Haemonchus contortus","volume":"105","author":"Jasmer","year":"2000","journal-title":"Mol. Biochem. Parasitol."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118987_bib171","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/bkcs.12519","article-title":"Investigation of benzimidazole anthelmintics as oral anticancer agents","volume":"43","author":"Jang","year":"2022","journal-title":"Bull. Kor. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.118987_bib172","article-title":"Stretchable tactile sensor with high sensitivity and dynamic stability based on vertically aligned urchin-shaped nanoparticles","volume":"14","author":"Yu","year":"2020","journal-title":"Mater. Today Phys."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib173","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-30158-6","article-title":"Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways","volume":"8","author":"Dogra","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib174","first-page":"1","article-title":"Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies","volume":"11","author":"Phan","year":"2014","journal-title":"Cancer Biol. Med."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118987_bib175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005758","article-title":"A metabolic core model elucidates how enhanced utilization of glucose and glutamine, with enhanced glutamine-dependent lactate production, promotes cancer cell growth: the WarburQ effect","volume":"13","author":"Damiani","year":"2017","journal-title":"PLoS Comput. Biol."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118987_bib176","doi-asserted-by":"crossref","first-page":"377","DOI":"10.4196\/kjpp.2022.26.5.377","article-title":"Anti-cancer effects of fenbendazole on 5-fluorouracil-resistant colorectal cancer cells","volume":"26","author":"Park","year":"2022","journal-title":"Korean J. Physiol. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib177","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91629-x","article-title":"Transcriptional drug repositioning and cheminformatics approach for differentiation therapy of leukaemia cells","volume":"11","author":"KalantarMotamedi","year":"2021","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118987_bib178","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2020.151075","article-title":"Microtubule-targeting agents and their impact on cancer treatment","volume":"99","author":"\u010cerm\u00e1k","year":"2020","journal-title":"Eur. J. Cell Biol."},{"issue":"22","key":"10.1016\/j.ejmech.2026.118987_bib179","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232214088","article-title":"Fenbendazole attenuates bleomycin-induced pulmonary fibrosis in mice via suppression of fibroblast-to-myofibroblast differentiation","volume":"23","author":"Wang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118987_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.109983","article-title":"Fenbendazole and its synthetic analog interfere with HeLa cells' proliferation and energy metabolism via inducing oxidative stress and modulating MEK3\/6-p38-MAPK pathway","volume":"361","author":"Peng","year":"2022","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2026.118987_bib181","article-title":"Edmond man says cheap drug for dogs cured his cancer","author":"Onstot","year":"2019","journal-title":"KOCO News"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib182","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12917-024-04056-1","article-title":"Preparation and evaluation of fenbendazole methyl-\u03b2-cyclodextrin inclusion complexes","volume":"20","author":"Ding","year":"2024","journal-title":"BMC Vet. Res."},{"key":"10.1016\/j.ejmech.2026.118987_bib183","first-page":"9506","volume":"vol. 12","author":"Priyanka","year":"2023"},{"key":"10.1016\/j.ejmech.2026.118987_bib186","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.semcancer.2017.02.009","article-title":"From ancient herb to modern drug: artemisia annua and artemisinin for cancer therapy","volume":"46","author":"Efferth","year":"2017","journal-title":"Semin. Cancer Biol."},{"issue":"4703","key":"10.1016\/j.ejmech.2026.118987_bib187","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1126\/science.3887571","article-title":"Qinghaosu (Artemisinin): an antimalarial drug from China","volume":"228","author":"Klayman","year":"1985","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.ejmech.2026.118987_bib188","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/med.21446","article-title":"Artemisinin as an anticancer drug: recent advances in target profiling and mechanisms of action","volume":"37","author":"Wong","year":"2017","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2026.118987_bib189","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.actatropica.2016.08.006","article-title":"Efficacy of artemisinin-based combination therapies for the treatment of falciparum malaria in Pakistan (2007-2015): in vivo response and dhfr and dhps mutations","volume":"164","author":"Kakar","year":"2016","journal-title":"Acta Trop."},{"issue":"52","key":"10.1016\/j.ejmech.2026.118987_bib190","doi-asserted-by":"crossref","first-page":"86803","DOI":"10.18632\/oncotarget.13466","article-title":"Niclosamide and its analogs are potent inhibitors of Wnt\/\u03b2-catenin, mTOR and STAT3 signaling in ovarian cancer","volume":"7","author":"Arend","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib191","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41418-019-0352-3","article-title":"Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis","volume":"27","author":"Chen","year":"2020","journal-title":"Cell Death Differ."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118987_bib192","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1074\/jbc.M110.144188","article-title":"The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials","volume":"286","author":"Mercer","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118987_bib193","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216596","article-title":"Dihydroartemisinin inhibits the development of colorectal cancer by GSK-3beta\/TCF7\/MMP9 pathway and synergies with capecitabine","volume":"582","author":"Dai","year":"2024","journal-title":"Cancer Lett."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118987_bib194","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24097844","article-title":"Anti-cancer effects of artesunate in human 3D tumor models of different complexity","volume":"24","author":"Niederreiter","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118987_bib195","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3390\/cancers16071321","article-title":"Antineoplastic drug synergy of artesunate with navitoclax in models of high-grade serous ovarian cancer","volume":"16","author":"McCorkle","year":"2024","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118987_bib196","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00280-018-3533-8","article-title":"A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies","volume":"81","author":"Deeken","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118987_bib197","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00280-016-2960-7","article-title":"Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study","volume":"77","author":"K\u00f6nig","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118987_bib198","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-017-4261-1","article-title":"Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33\/2)","volume":"164","author":"von Hagens","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejmech.2026.118987_bib199","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.phymed.2018.09.178","article-title":"Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33\/2)","volume":"54","author":"von Hagens","year":"2019","journal-title":"Phytomedicine"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118987_bib205","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0306-3623(96)00149-8","article-title":"The mechanisms of action of antiprotozoal and anthelmintic drugs in man","volume":"28","author":"Frayha","year":"1997","journal-title":"Gen. Pharmacol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118987_bib206","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0163-7258(82)90064-X","article-title":"The biology and toxicology of molluscicides, Bayluscide","volume":"19","author":"Andrews","year":"1982","journal-title":"Pharmacol. Therapeut."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118987_bib207","doi-asserted-by":"crossref","first-page":"550","DOI":"10.7326\/0003-4819-102-4-550","article-title":"Niclosamide therapy for tapeworm infections","volume":"102","author":"Richard","year":"1985","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118987_bib208","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4102\/jsava.v70i2.756","article-title":"The pharmacology of halogenated salicylanilides and their anthelmintic use in animals","volume":"70","author":"Swan","year":"1999","journal-title":"J. S. Afr. Vet. Assoc."},{"key":"10.1016\/j.ejmech.2026.118987_bib209","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejpb.2019.05.004","article-title":"Niclosamide repositioning for treating cancer: challenges and nano-based drug delivery opportunities","volume":"141","author":"Barbosa","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118987_bib210","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/nm.3699","article-title":"Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves diabetic symptoms in mice","volume":"20","author":"Tao","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.118987_bib211","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0099-5428(05)32002-8","article-title":"Niclosamide: comprehensive profile","volume":"32","author":"Al-Hadiya","year":"2005","journal-title":"Profiles Drug Subst. Excipients Relat. Methodol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib212","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2014.04.003","article-title":"Multi-targeted therapy of cancer by niclosamide: a new application for an old drug","volume":"349","author":"Li","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2026.118987_bib213","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12935-015-0196-y","article-title":"Suramin inhibits cell proliferation in ovarian and cervical cancer by downregulating heparanase expression","volume":"15","author":"Li","year":"2015","journal-title":"Cancer Cell Int."},{"issue":"27","key":"10.1016\/j.ejmech.2026.118987_bib214","doi-asserted-by":"crossref","first-page":"42126","DOI":"10.18632\/oncotarget.9704","article-title":"Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt\/\u03b2-catenin signaling","volume":"7","author":"Yin","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118987_bib215","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41419-017-0092-6","article-title":"Effect of mitochondrial uncouplers niclosamide ethanolamine (NEN) and oxyclozanide on hepatic metastasis of colon cancer","volume":"9","author":"Alasadi","year":"2018","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib216","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc3419","article-title":"WNT signalling pathways as therapeutic targets in cancer","volume":"13","author":"Anastas","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib217","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"issue":"5155","key":"10.1016\/j.ejmech.2026.118987_bib218","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1126\/science.8140422","article-title":"Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6","volume":"264","author":"Zhong","year":"1994","journal-title":"Science"},{"issue":"5164","key":"10.1016\/j.ejmech.2026.118987_bib219","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1126\/science.8197455","article-title":"Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins","volume":"264","author":"Darnell","year":"1994","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib220","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/clinchem\/45.1.7","article-title":"New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases","volume":"45","author":"Chen","year":"1999","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ejmech.2026.118987_bib221","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev-biophys-083012-130338","article-title":"Molecular basis of NF-\u03baB signaling","volume":"42","author":"Napetschnig","year":"2013","journal-title":"Annu. Rev. Biophys."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118987_bib222","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1158\/0008-5472.CAN-06-3958","article-title":"Notch signaling, gamma-secretase inhibitors, and cancer therapy","volume":"67","author":"Shih","year":"2007","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118987_bib223","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-09-2823","article-title":"Targeting notch to target cancer stem cells","volume":"16","author":"Pannuti","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"34","key":"10.1016\/j.ejmech.2026.118987_bib224","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1038\/sj.onc.1209598","article-title":"Mitochondria as therapeutic targets for cancer chemotherapy","volume":"25","author":"Galluzzi","year":"2006","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.ejmech.2026.118987_bib225","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5483\/BMBRep.2011.44.8.517","article-title":"Niclosamide induces mitochondria fragmentation and promotes both apoptotic and autophagic cell death","volume":"44","author":"Park","year":"2011","journal-title":"BMB Rep."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118987_bib226","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1053\/j.gastro.2017.02.039","article-title":"Computational discovery of niclosamide ethanolamine, a repurposed drug candidate that reduces growth of hepatocellular carcinoma cells in vitro and in mice by inhibiting cell division cycle 37 signaling","volume":"152","author":"Chen","year":"2017","journal-title":"Gastroenterology"},{"issue":"13","key":"10.1016\/j.ejmech.2026.118987_bib227","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/jnci\/djr190","article-title":"Novel effect of antihelminthic niclosamide on S100A4-mediated metastatic progression in colon cancer","volume":"103","author":"Sack","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118987_bib228","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1158\/0008-5472.CAN-10-3978","article-title":"Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations","volume":"71","author":"Osada","year":"2011","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118987_bib229","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1021\/ml100146z","article-title":"Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway","volume":"1","author":"Ren","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118987_bib230","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1158\/1535-7163.MCT-13-0608","article-title":"Disruption of STAT3 by niclosamide reverses radioresistance of human lung cancer","volume":"13","author":"You","year":"2014","journal-title":"Mol. Cancer Therapeut."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118987_bib231","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jsps.2021.04.004","article-title":"Anthelmintics for drug repurposing: opportunities and challenges","volume":"29","author":"Alavi","year":"2021","journal-title":"Saudi Pharm. J."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib237","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00436-023-08027-7","article-title":"100 years since the publication of the suramin formula","volume":"123","author":"Steverding","year":"2023","journal-title":"Parasitol. Res."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118987_bib238","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0035-9203(23)80032-3","article-title":"The treatment of human trypanosomiasis by \u201cBayer 205\u201d","volume":"16","author":"Low","year":"1923","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib239","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1756-3305-1-3","article-title":"The history of African trypanosomiasis","volume":"1","author":"Steverding","year":"2008","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.ejmech.2026.118987_bib240","series-title":"The Treatment of Animal Trypanosomiases By\" Bayer 205","author":"Van Saceghem","year":"1925"},{"key":"10.1016\/j.ejmech.2026.118987_bib241","series-title":"25 Years' Experience of the Use of Bayer 205 (Germanin, Naganol) for Trypanosomiasis","author":"Hetzel","year":"1942"},{"issue":"30","key":"10.1016\/j.ejmech.2026.118987_bib242","doi-asserted-by":"crossref","first-page":"10281","DOI":"10.1074\/jbc.RA120.014375","article-title":"Suramin and NF449 are IP5K inhibitors that disrupt inositol hexakisphosphate-mediated regulation of cullin-RING ligase and sensitize cancer cells to MLN4924\/pevonedistat","volume":"295","author":"Zhang","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"24","key":"10.1016\/j.ejmech.2026.118987_bib243","doi-asserted-by":"crossref","first-page":"8331","DOI":"10.1074\/jbc.RA120.012355","article-title":"Suramin exposure alters cellular metabolism and mitochondrial energy production in African trypanosomes","volume":"295","author":"Zoltner","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118987_bib244","doi-asserted-by":"crossref","first-page":"18","DOI":"10.15698\/mic2023.02.790","article-title":"The role of invariant surface glycoprotein 75 in xenobiotic acquisition by African trypanosomes","volume":"10","author":"Makarov","year":"2023","journal-title":"Microb. Cell"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118987_bib245","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01168-19","article-title":"100 years of suramin","volume":"64","author":"Wiedemar","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib246","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","article-title":"FGF\/FGFR signaling in health and disease","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.118987_bib247","article-title":"Synthesis of novel suramin analogs with anti-proliferative activity via FGF1 and FGFRD2 blockade","volume":"9","author":"Parveen","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2026.118987_bib248","doi-asserted-by":"crossref","DOI":"10.1016\/j.exppara.2024.108744","article-title":"Suramin: effectiveness of analogues reveals structural features that are important for the potent trypanocidal activity of the drug","volume":"260","author":"Steverding","year":"2024","journal-title":"Exp. Parasitol."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118987_bib249","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26041643","article-title":"HMGA2 overexpression in papillary thyroid cancer promotes thyroid cell dedifferentiation and invasion, and these effects are counteracted by suramin","volume":"26","author":"Van Branteghem","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118987_bib250","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115814","article-title":"Suramin, a drug for the treatment of trypanosomiasis, reduces the prothrombotic and metastatic phenotypes of colorectal cancer cells by inhibiting hepsin","volume":"168","author":"Zaragoza-Huesca","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib251","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1208\/s12248-014-9703-7","article-title":"Pharmacodynamics of telomerase inhibition and telomere shortening by noncytotoxic suramin","volume":"17","author":"Gan","year":"2015","journal-title":"AAPS J."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118987_bib252","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1042\/BJ20150913","article-title":"Inhibition of Wnt signalling and breast tumour growth by the multi-purpose drug suramin through suppression of heterotrimeric G proteins and Wnt endocytosis","volume":"473","author":"Koval","year":"2016","journal-title":"Biochem. J."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118987_bib253","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.1996.14.5.1626","article-title":"Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy","volume":"14","author":"Rosen","year":"1996","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118987_bib254","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1200\/JCO.2000.18.7.1440","article-title":"Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone","volume":"18","author":"Small","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib255","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/cncr.11867","article-title":"A phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma","volume":"100","author":"Vogelzang","year":"2004","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ejmech.2026.118987_bib256","first-page":"3303","article-title":"Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer","volume":"9","author":"Villalona-Calero","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118987_bib257","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00280-010-1252-x","article-title":"Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer","volume":"66","author":"Lam","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib258","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00280-012-1887-x","article-title":"Phase I\/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes","volume":"70","author":"Lustberg","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118987_bib261","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02582-16","article-title":"Praziquantel for schistosomiasis: single-drug metabolism revisited, mode of action, and resistance","volume":"61","author":"Vale","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2026.118987_bib262","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/QCO.0b013e328318978f","article-title":"Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis","volume":"21","author":"Doenhoff","year":"2009","journal-title":"Curr. Opin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118987_bib263","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/QCO.0b013e328318978f","article-title":"Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis","volume":"21","author":"Doenhoff","year":"2008","journal-title":"Curr. Opin. Infect. Dis."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118987_bib264","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051721","article-title":"Praziquantel synergistically enhances paclitaxel efficacy to inhibit cancer cell growth","volume":"7","author":"Wu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.118987_bib265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7150\/oncm.20563","article-title":"Repurposing of anthelminthics as anticancer drugs","volume":"3","author":"Hamilton","year":"2018","journal-title":"Oncomedicine"},{"key":"10.1016\/j.ejmech.2026.118987_bib266","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1001\/jama.1964.03070060121016","article-title":"Treatment of pinworm infections with reduced single dose of pyrvinium pamoate","volume":"189","author":"Beck","year":"1964","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2026.118987_bib267","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0022-3476(62)80042-0","article-title":"Pyrvinium pamoate in the treatment of pinworm infection (enterobiasis) in the home","volume":"60","author":"Turner","year":"1962","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ejmech.2026.118987_bib268","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4269\/ajtmh.1962.11.89","article-title":"Anthelmintic studies on pyrvinium pamoate (Povan) and other drugs in rodents, dogs, and monkeys","volume":"11","author":"Thompson","year":"1962","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"5319","key":"10.1016\/j.ejmech.2026.118987_bib269","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/bmj.2.5319.1583","article-title":"Single-dose treatment of oxyuriasis with pyrvinium embonate","volume":"2","author":"Desai","year":"1962","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejmech.2026.118987_bib270","first-page":"551","article-title":"[Treatment of oxyuriasis in children under 10 years of age by a single dose of pyrvinium embonate (Povanyl). (Apropos of 25 recent cases)]","volume":"17","author":"Garin","year":"1962","journal-title":"Pediatrie"},{"issue":"6","key":"10.1016\/j.ejmech.2026.118987_bib271","first-page":"422","article-title":"[Treatment of enterobiasis with pyrantel pamoate. Comparative study with pyrvinium pamoate]","volume":"13","author":"Baranski","year":"1971","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"issue":"11","key":"10.1016\/j.ejmech.2026.118987_bib272","first-page":"270","article-title":"Comparison of pyrantel pamoate syrup and pyrvinium pamoate syrup in the treatment of enterobiasis in Egypt","volume":"77","author":"Nassif","year":"1974","journal-title":"J. Trop. Med. Hyg."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118987_bib273","first-page":"34","article-title":"[Comparative effectiveness and tolerance in the vanquin, combantrin and vermox treatments of enterobiasis]","volume":"49","author":"Alekseeva","year":"1980","journal-title":"Med Parazitol (Mosk)"},{"issue":"12","key":"10.1016\/j.ejmech.2026.118987_bib274","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10123249","article-title":"Pyrvinium pamoate: past, present, and future as an anti-cancer drug","volume":"10","author":"Schultz","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib275","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0022-3476(71)80278-0","article-title":"Treatment of parasitic infestation in children with malignant neoplasms","volume":"78","author":"Aur","year":"1971","journal-title":"J. Pediatr."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118987_bib276","doi-asserted-by":"crossref","first-page":"630","DOI":"10.11150\/kansenshogakuzasshi1970.64.630","article-title":"[A case of Pneumocystis carinii pneumonia with hyperinfection of Strongyloides stercoralis complicated with smoldering adult T-cell leukemia]","volume":"64","author":"Udaka","year":"1990","journal-title":"Kansenshogaku Zasshi"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118987_bib277","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.amjms.2017.11.017","article-title":"Pyrvinium sensitizes clear cell renal cell carcinoma response to chemotherapy via casein kinase 1\u03b1-Dependent inhibition of Wnt\/\u03b2-Catenin","volume":"355","author":"Cui","year":"2018","journal-title":"Am. J. Med. Sci."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118987_bib278","doi-asserted-by":"crossref","DOI":"10.1097\/CAD.0000000000000747","article-title":"Casein kinase 1\u03b1-dependent inhibition of Wnt\/\u03b2-catenin selectively targets nasopharyngeal carcinoma and increases chemosensitivity","volume":"30","author":"Li","year":"2019","journal-title":"Anti Cancer Drugs"},{"issue":"51","key":"10.1016\/j.ejmech.2026.118987_bib279","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1021\/acs.biochem.9b00891","article-title":"The CK1\u03b1 activator pyrvinium enhances the catalytic efficiency (k(cat)\/K(m)) of CK1\u03b1","volume":"58","author":"Shen","year":"2019","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib280","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.canlet.2011.12.034","article-title":"Pyrvinium pamoate inhibits proliferation of myeloma\/erythroleukemia cells by suppressing mitochondrial respiratory complex I and STAT3","volume":"319","author":"Harada","year":"2012","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118987_bib281","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jb\/mvs041","article-title":"An anticancer agent, pyrvinium pamoate inhibits the NADH-fumarate reductase system--a unique mitochondrial energy metabolism in tumour microenvironments","volume":"152","author":"Tomitsuka","year":"2012","journal-title":"J. Biochem."},{"issue":"29","key":"10.1016\/j.ejmech.2026.118987_bib282","doi-asserted-by":"crossref","first-page":"45249","DOI":"10.18632\/oncotarget.9932","article-title":"Inhibiting cytoplasmic accumulation of HuR synergizes genotoxic agents in urothelial carcinoma of the bladder","volume":"7","author":"Guo","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.ejmech.2026.118987_bib283","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1021\/cb800054w","article-title":"A cellular conformation-based screen for androgen receptor inhibitors","volume":"3","author":"Jones","year":"2008","journal-title":"ACS Chem. Biol."},{"issue":"12","key":"10.1016\/j.ejmech.2026.118987_bib284","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003951","article-title":"Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy","volume":"3","author":"Yu","year":"2008","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.ejmech.2026.118987_bib285","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1158\/0008-5472.CAN-14-0317","article-title":"Pyrvinium attenuates Hedgehog signaling downstream of smoothened","volume":"74","author":"Li","year":"2014","journal-title":"Cancer Res."},{"issue":"23","key":"10.1016\/j.ejmech.2026.118987_bib286","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.70222","article-title":"Pyrvinium pamoate alone and with gemcitabine exhibits anti-pancreatic cancer activity in 2D and 3D cell culture models","volume":"28","author":"Serala","year":"2024","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejmech.2026.118987_bib287","article-title":"Integrative analysis reveals therapeutic potential of pyrvinium pamoate in Merkel cell carcinoma","author":"Yang","year":"2024","journal-title":"bioRxiv"},{"issue":"10","key":"10.1016\/j.ejmech.2026.118987_bib288","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-073839","article-title":"Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancreatic ductal adenocarcinoma","volume":"13","author":"Ponzini","year":"2023","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/j.ejmech.2026.118987_bib290","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pt.2012.04.003","article-title":"Levamisole receptors: a second awakening","volume":"28","author":"Martin","year":"2012","journal-title":"Trends Parasitol."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118987_bib291","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/avj.13162","article-title":"Anthelmintic resistance of gastrointestinal nematodes in dairy calves within a pasture-based production system of south West Western Australia","volume":"100","author":"Mauger","year":"2022","journal-title":"Aust. Vet. J."},{"issue":"14","key":"10.1016\/j.ejmech.2026.118987_bib292","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.3390\/ijms21144957","article-title":"Repositioning of anthelmintic drugs for the treatment of cancers of the digestive System","volume":"21","author":"Laudisi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118987_bib293","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.biopha.2018.06.113","article-title":"Antitumor and immune-modulatory efficacy of dual-treatment based on levamisole and\/or taurine in Ehrlich ascites carcinoma-bearing mice","volume":"106","author":"Ibrahim","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2026.118987_bib294","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118034","article-title":"Levamisole enhances DR4-independent apoptosis induced by TRAIL through inhibiting the activation of JNK in lung cancer","volume":"257","author":"Qiao","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2026.118987_bib295","first-page":"365","article-title":"Therapeutic evaluation of anti-angiogenic and chemotherapy with or without cox-2 inhibitor and immunomodulator drug in the management of canine mammary neoplasm","volume":"35","author":"Dileepkumar","year":"2015","journal-title":"Pak. Vet. J."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118987_bib296","doi-asserted-by":"crossref","first-page":"566","DOI":"10.4103\/ijc.IJC_349_17","article-title":"Effect of levamisole on expression of CD138 and interleukin-6 in human multiple myeloma cell lines","volume":"54","author":"Nageshwari","year":"2017","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.ejmech.2026.118987_bib297","first-page":"137","article-title":"Pharmacokinetics of levamisole","volume":"4","author":"Adams","year":"1978","journal-title":"J. Rheumatol. Suppl."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib298","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/bdd.2510070110","article-title":"Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine","volume":"7","author":"Kouassi","year":"1986","journal-title":"Biopharm Drug Dispos."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118987_bib299","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3390\/cancers5030762","article-title":"Influence of levamisole and other angiogenesis inhibitors on angiogenesis and endothelial cell morphology in vitro","volume":"5","author":"Friis","year":"2013","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ejmech.2026.118987_bib300","first-page":"1149","article-title":"Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study","volume":"58","author":"Ahnen","year":"1998","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118987_bib301","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1080\/02841860902755244","article-title":"Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian gastrointestinal cancer group","volume":"48","author":"Dahl","year":"2009","journal-title":"Acta Oncol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118987_bib302","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJM199002083220602","article-title":"Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma","volume":"322","author":"Moertel","year":"1990","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib303","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1200\/JCO.1998.16.1.295","article-title":"Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer","volume":"16","author":"O'Connell","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118987_bib304","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202350562","article-title":"Levamisole suppresses activation and proliferation of human T cells by the induction of a p53-dependent DNA damage response","volume":"53","author":"Khan","year":"2023","journal-title":"Eur. J. Immunol."},{"issue":"11","key":"10.1016\/j.ejmech.2026.118987_bib305","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1200\/JCO.1999.17.11.3553","volume":"17","author":"Wolmark","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.ejmech.2026.118987_bib306","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1097\/CM9.0000000000000539","article-title":"Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"132","author":"Weng","year":"2019","journal-title":"Chin. Med. J."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib307","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13071-021-04605-9","article-title":"Anthelmintic efficacy of fenbendazole and levamisole in native fowl in northern Iran","volume":"14","author":"Saemi Soudkolaei","year":"2021","journal-title":"Parasites Vectors"},{"issue":"42","key":"10.1016\/j.ejmech.2026.118987_bib134","doi-asserted-by":"crossref","first-page":"71512","DOI":"10.18632\/oncotarget.17292","article-title":"Repurposing Albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer","volume":"8","author":"Ghasemi","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.ejmech.2026.118987_bib135","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24112152","article-title":"Benzimidazoles downregulate Mdm2 and MdmX and activate p53 in MdmX overexpressing tumor cells","volume":"24","author":"Mrkvov\u00e1","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118987_bib136","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2076579","article-title":"Antitumor effect of albendazole on cutaneous squamous cell carcinoma (SCC) cells","volume":"2019","author":"Zhang","year":"2019","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.ejmech.2026.118987_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2020.104930","article-title":"An analysis of mitotic catastrophe induced cell responses in melanoma cells exposed to flubendazole","volume":"68","author":"Rudolf","year":"2020","journal-title":"Toxicol. Vitro"},{"issue":"7","key":"10.1016\/j.ejmech.2026.118987_bib185","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.7150\/ijbs.81415","article-title":"Drug repurposing flubendazole to suppress tumorigenicity via PCSK9-dependent inhibition and potentiate lenvatinib therapy for hepatocellular carcinoma","volume":"19","author":"Jin","year":"2023","journal-title":"Int. J. Biol. Sci."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118987_bib201","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.108458","article-title":"Artesunate enhances the efficacy of enzalutamide in advanced prostate cancer","volume":"301","author":"Wang","year":"2025","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118987_bib202","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.2147\/OTT.S249046","article-title":"Dihydroartemisinin prevents progression and metastasis of head and neck squamous cell carcinoma by inhibiting polarization of macrophages in tumor microenvironment","volume":"13","author":"Chen","year":"2020","journal-title":"OncoTargets Ther."},{"issue":"18","key":"10.1016\/j.ejmech.2026.118987_bib203","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.7150\/jca.25082","article-title":"Dihydroartemisinin enhances VEGFR1 expression through up-regulation of ETS-1 transcription factor","volume":"9","author":"Niu","year":"2018","journal-title":"J. Cancer"},{"issue":"3","key":"10.1016\/j.ejmech.2026.118987_bib204","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jdermsci.2020.08.001","article-title":"Dihydroartemisinin inhibits melanoma by regulating CTL\/treg anti-tumor immunity and STAT3-mediated apoptosis via IL-10 dependent manner","volume":"99","author":"Yu","year":"2020","journal-title":"J. Dermatol. Sci."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118987_bib232","article-title":"Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.ejmech.2026.118987_bib233","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1158\/1078-0432.CCR-12-2895","article-title":"Anticancer effects of niclosamide in human glioblastoma","volume":"19","author":"Wieland","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118987_bib234","first-page":"549","article-title":"Niclosamide inhibits the cell proliferation and enhances the responsiveness of esophageal cancer cells to chemotherapeutic agents","volume":"43","author":"Lee","year":"2020","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib235","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jss.2016.03.051","article-title":"The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway","volume":"203","author":"Monin","year":"2016","journal-title":"J. Surg. Res."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118987_bib236","article-title":"Drug screening identifies niclosamide as an inhibitor of breast cancer stem-like cells","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.118987_bib259","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.2147\/DDDT.S416325","article-title":"Phase I, single-dose study to assess the pharmacokinetics and safety of suramin in healthy Chinese volunteers","volume":"17","author":"Wu","year":"2023","journal-title":"Drug Des. Dev. Ther."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118987_bib260","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/jnci\/84.1.38","article-title":"Inhibition of breast cancer growth by suramin","volume":"84","author":"Vignon","year":"1992","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118987_bib289","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101048","article-title":"High-throughput drug screening reveals Pyrvinium pamoate as effective candidate against pediatric MLL-rearranged acute myeloid leukemia","volume":"14","author":"Wander","year":"2021","journal-title":"Transl. Oncol."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118987_bib308","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043632","article-title":"Novel levamisole derivative induces extrinsic pathway of apoptosis in cancer cells and inhibits tumor progression in mice","volume":"7","author":"Hegde","year":"2012","journal-title":"PLoS One"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:10:17Z","timestamp":1783923017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426004320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":307,"alternative-id":["S0223523426004320"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118987","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiparasitic agents in oncology: Innovative mechanisms, emerging evidence and clinical potential in cancer treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118987","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118987"}}